OHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omega Healthcare Investors, Inc. (OHI) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown solid financial growth in its latest quarter and hedge funds are increasing their positions, the recent analyst downgrades and lowered price targets, coupled with regulatory and competitive pressures, suggest caution. The technical indicators are neutral to slightly bullish, but the lack of strong Intellectia Proprietary Trading Signals and mixed sentiment in options data further supports a hold recommendation.
The MACD is positive and expanding, indicating a bullish trend. The RSI is neutral at 57.008, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 46.85 and 47.498, while support levels are at 44.753 and 44.105. The stock is trading near its pivot point at 45.801, suggesting limited immediate upside.
Financials for Q4 2025 showed strong revenue growth (+14.28% YoY), net income growth (+44.53% YoY), and EPS growth (+34.15% YoY).
Options data indicates bearish sentiment. Gross margin slightly declined YoY, and there is no recent congress trading data to provide additional confidence.
In Q4 2025, Omega Healthcare reported strong financial growth: revenue increased by 14.28% YoY to $319.2M, net income rose by 44.53% YoY to $163.8M, and EPS improved by 34.15% YoY to $0.55. However, gross margin slightly declined to 98.63% (-0.14% YoY).
Recent analyst sentiment is mixed to negative. BofA downgraded the stock to Underperform with a price target of $46, citing regulatory and competitive pressures. Other analysts have maintained neutral or hold ratings, with price targets ranging from $45 to $52. Earlier in the year, some analysts were more optimistic, but recent downgrades overshadow prior positive outlooks.
